{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:50:28Z","timestamp":1780350628748,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Department of Health of Zhejiang province","doi-asserted-by":"crossref","award":["2023KY713"],"award-info":[{"award-number":["2023KY713"]}],"id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10760-6","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:55:21Z","timestamp":1742176521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp"],"prefix":"10.1186","volume":"25","author":[{"given":"Lushun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"10760_CR1","doi-asserted-by":"publisher","first-page":"744431","DOI":"10.3389\/fcimb.2021.744431","volume":"11","author":"Y Yao","year":"2021","unstructured":"Yao Y, Falgenhauer L, Falgenhauer J, Hauri AM, Heinm\u00fcller P, Domann E, Chakraborty T, Imirzalioglu C. Carbapenem-Resistant Citrobacter spp. As an emerging concern in the Hospital-Setting: results from a Genome-Based regional surveillance study. Front Cell Infect Microbiol. 2021;11:744431. https:\/\/doi.org\/10.3389\/fcimb.2021.744431","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10760_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1086\/515106","volume":"28","author":"TI Doran","year":"1999","unstructured":"Doran TI. The role of Citrobacter in clinical disease of children: review. Clin Infect Dis. 1999;28(2):384\u201394. https:\/\/doi.org\/10.1086\/515106","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10760_CR3","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1093\/jac\/dkx325","volume":"72","author":"DM Arana","year":"2017","unstructured":"Arana DM, Ortega A, Gonz\u00e1lez-Barber\u00e1 E, Lara N, Bautista V, G\u00f3mez-Ru\u00edz D, S\u00e1ez D, Fern\u00e1ndez-Romero S, Aracil B, P\u00e9rez-V\u00e1zquez M, Campos J, Oteo J, Spanish Antibiotic Resistance Surveillance Programme Collaborating Group. Carbapenem-resistant Citrobacter spp. Isolated in Spain from 2013 to 2015 produced a variety of carbapenemases including VIM-1, OXA-48, KPC-2, NDM-1 and VIM-2. J Antimicrob Chemother. 2017;72(12):3283\u20137. https:\/\/doi.org\/10.1093\/jac\/dkx325","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10760_CR4","doi-asserted-by":"publisher","first-page":"e0414422","DOI":"10.1128\/spectrum.04144-22","volume":"11","author":"D Nobrega","year":"2023","unstructured":"Nobrega D, Peirano G, Matsumura Y, Pitout JDD. Molecular epidemiology of global Carbapenemase-Producing Citrobacter spp. (2015\u20132017). Microbiol Spectr. 2023;11(2):e0414422. https:\/\/doi.org\/10.1128\/spectrum.04144-22","journal-title":"Microbiol Spectr"},{"issue":"9","key":"10760_CR5","doi-asserted-by":"publisher","first-page":"e00275","DOI":"10.1128\/JCM.00275-20","volume":"58","author":"A Babiker","year":"2020","unstructured":"Babiker A, Evans DR, Griffith MP, McElheny CL, Hassan M, Clarke LG, Mettus RT, Harrison LH, Doi Y, Shields RK, Van Tyne D. Clinical and genomic epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. At a tertiary health care center over 2 decades. J Clin Microbiol. 2020;58(9):e00275\u201320. https:\/\/doi.org\/10.1128\/JCM.00275-20","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10760_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmii.2016.08.016","volume":"51","author":"LH Liu","year":"2018","unstructured":"Liu LH, Wang NY, Wu AY, Lin CC, Lee CM, Liu CP. Citrobacter freundii bacteremia: risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018;51(4):565\u201372. https:\/\/doi.org\/10.1016\/j.jmii.2016.08.016","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10760_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3947\/ic.2019.51.1.1","volume":"51","author":"R Lee","year":"2019","unstructured":"Lee R, Choi SM, Jo SJ, Lee J, Cho SY, Kim SH, Lee DG, Jeong HS. Clinical characteristics and antimicrobial susceptibility trends in Citrobacter bacteremia: an 11-Year Single-Center experience. Infect Chemother. 2019;51(1):1\u20139. https:\/\/doi.org\/10.3947\/ic.2019.51.1.1","journal-title":"Infect Chemother"},{"key":"10760_CR8","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant Gram-Negative infections. Clin Infect Dis 2023;18:ciad428. https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"issue":"6","key":"10760_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/jac\/dkh235","volume":"53","author":"S Underwood","year":"2004","unstructured":"Underwood S, Avison MB. Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004;53(6):1076\u201380. https:\/\/doi.org\/10.1093\/jac\/dkh235","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10760_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jac\/dkv346","volume":"71","author":"PN Harris","year":"2016","unstructured":"Harris PN, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR, Pandeya N, Doi Y, Huh K, O\u2019Neal CS, Talbot TR, Paterson DL. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections (BSIs) caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71(2):296\u2013306. https:\/\/doi.org\/10.1093\/jac\/dkv346","journal-title":"J Antimicrob Chemother"},{"key":"10760_CR11","doi-asserted-by":"publisher","first-page":"780365","DOI":"10.3389\/fcimb.2021.780365","volume":"11","author":"W Yu","year":"2021","unstructured":"Yu W, Xiong L, Luo Q, Chen Y, Ji J, Ying C, Liu Z, Xiao Y. In vitro activities comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China. Front Cell Infect Microbiol. 2021;11:780365. https:\/\/doi.org\/10.3389\/fcimb.2021.780365","journal-title":"Front Cell Infect Microbiol"},{"key":"10760_CR12","doi-asserted-by":"publisher","first-page":"771910","DOI":"10.3389\/fphar.2021.771910","volume":"12","author":"W Yu","year":"2021","unstructured":"Yu W, Chen Y, Shen P, Ji J, Ying C, Liu Z, Xiong L, Qiu Y, Xiao Y. Antibacterial activity and optimal treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam against bloodstream infections caused by Carbapenem-Resistant Klebsiella pneumoniae. Front Pharmacol. 2021;12:771910. https:\/\/doi.org\/10.3389\/fphar.2021.771910","journal-title":"Front Pharmacol"},{"issue":"6","key":"10760_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/jac\/dki375","volume":"56","author":"S Jaruratanasirikul","year":"2005","unstructured":"Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. Pharmacokinetics of Imipenem in healthy volunteers following administration by 2\u00a0h or 0.5\u00a0h infusion. J Antimicrob Chemother. 2005;56(6):1163\u20135. https:\/\/doi.org\/10.1093\/jac\/dki375","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10760_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","volume":"28","author":"JW Mouton","year":"1995","unstructured":"Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28(4):275\u201386. https:\/\/doi.org\/10.2165\/00003088-199528040-00002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10760_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","volume":"68","author":"LS Lee","year":"2010","unstructured":"Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, S\u00f6rgel F, Jones RN, Drusano GL, Bertino JS Jr. Comparison of 30-min and 3-h infusion regimens for Imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68(3):251\u20138. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.06.012","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10760_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijantimicag.2007.06.005","volume":"30","author":"H Wang","year":"2007","unstructured":"Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007;30(5):452\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.06.005","journal-title":"Int J Antimicrob Agents"},{"issue":"15","key":"10760_CR17","doi-asserted-by":"publisher","first-page":"2300528","DOI":"10.2807\/1560-7917.ES.2024.29.15.2300528","volume":"29","author":"J Sommer","year":"2024","unstructured":"Sommer J, Reiter H, Sattler J, Cacace E, Eisfeld J, Gatermann S, Hamprecht A, G\u00f6ttig S. Emergence of OXA-48-like producing Citrobacter species, Germany, 2011 to 2022. Euro Surveill. 2024;29(15):2300528. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.15.2300528","journal-title":"Euro Surveill"},{"issue":"6","key":"10760_CR18","doi-asserted-by":"publisher","first-page":"e0036623","DOI":"10.1128\/msphere.00366-23","volume":"8","author":"L Biez","year":"2023","unstructured":"Biez L, Bonnin RA, Emeraud C, Birer A, Jousset AB, Naas T, Dortet L. Nationwide molecular epidemiology of carbapenemase-producing Citrobacter spp. In France In 2019 and 2020. mSphere. 2023;8(6):e0036623. https:\/\/doi.org\/10.1128\/msphere.00366-23","journal-title":"mSphere"},{"key":"10760_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jgar.2022.04.014","volume":"29","author":"Y Li","year":"2022","unstructured":"Li Y, Fang C, Qiu Y, Dai X, Zhang L. Genomic characterization of a carbapenem-resistant Citrobacter freundii cocarrying bla(KPC-2) and bla(NDM-1). J Glob Antimicrob Resist. 2022;29:289\u201392. https:\/\/doi.org\/10.1016\/j.jgar.2022.04.014","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10760_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12941-024-00699-y","volume":"23","author":"J Ma","year":"2024","unstructured":"Ma J, Xu R, Li W, Liu M, Ding X. Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying bla(OXA-48) and bla(NDM-1). Ann Clin Microbiol Antimicrob. 2024;23(1):38. https:\/\/doi.org\/10.1186\/s12941-024-00699-y","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"10760_CR21","doi-asserted-by":"publisher","first-page":"e0251022","DOI":"10.1128\/spectrum.02510-22","volume":"10","author":"X Luo","year":"2022","unstructured":"Luo X, Yu L, Feng J, Zhang J, Zheng C, Hu D, Dai P, Xu M, Li P, Lin R, Mu K. Emergence of extensively Drug-Resistant ST170 Citrobacter portucalensis with plasmids pK218-KPC, pK218-NDM, and pK218-SHV from a tertiary hospital, China. Microbiol Spectr. 2022;10(5):e0251022. https:\/\/doi.org\/10.1128\/spectrum.02510-22","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10760_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1128\/AAC.35.5.983","volume":"35","author":"ML van Ogtrop","year":"1991","unstructured":"van Ogtrop ML, Guiot HF, Mattie H, van Strijen E, Sekh BR, van Furth R. Modulation of the intestinal flora of mice by treatment with Aztreonam and tigemonam. Antimicrob Agents Chemother. 1991;35(5):983\u20135. https:\/\/doi.org\/10.1128\/AAC.35.5.983","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10760_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cit395","volume":"57","author":"PD Tamma","year":"2013","unstructured":"Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. The use of cefepime for treating AmpC \u03b2-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781\u20138. https:\/\/doi.org\/10.1093\/cid\/cit395","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10760_CR24","doi-asserted-by":"publisher","first-page":"106289","DOI":"10.1016\/j.ijantimicag.2021.106289","volume":"57","author":"A Eisert","year":"2021","unstructured":"Eisert A, Lanckohr C, Frey J, Frey O, Wicha SG, Horn D, Ellger B, Schuerholz T, Marx G, Simon TP. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study. Int J Antimicrob Agents. 2021;57(3):106289. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106289","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10760_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1871526520666200227102013","volume":"21","author":"M Monajati","year":"2021","unstructured":"Monajati M, Ala S, Aliyali M, Ghasemian R, Heidari F, Ahanjan M, Moradi S, Sharifpour A, Mojtahedzadeh M, Salehifar E. Clinical effectiveness of a high dose versus the standard dose of meropenem in Ventilator-associated pneumonia caused by multidrugresistant bacteria: A randomized, Single-blind clinical trial. Infect Disord Drug Targets. 2021;21(2):274\u201383. https:\/\/doi.org\/10.2174\/1871526520666200227102013","journal-title":"Infect Disord Drug Targets"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10760-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:55:23Z","timestamp":1742176523000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10760-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10760"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10760-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare no ethical competing interest. This study was conducted following the Declaration of Helsinki and obtained approval from the clinical research ethics committee of The First Affiliated Hospital, Zhejiang University School of Medicine [No. 2018\u2009\u2212\u2009752]. The need for consent to participate was deemed unnecessary according to the clinical research ethics committee of The First Affiliated Hospital, Zhejiang University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}